Translational Medicine
Open Access

Abzymes as highly informative and unique biomarkers of the newest generation to monitor chronic autoimmune disorders at subclinical and clinical stages to predict features of the course

14^th Annual Conference on Translational Medicine and Oncologists Meet

November 28-30, 2016 San Francisco, USA

Sergey Suchkov

I M Sechenov First Moscow State Medical University, Russia

Keynote: Transl Med

Abstract :

Abs against myelin basic protein (MBP), cardiac myosine (CM) and thyroid Ags (TPO, T3 and T4) endowing with proteolytic activity (Ab-proteases) are of great value to monitor chronic auto-immune inflammation and to thus illustrate the evolution of either of the above-mentioned auto-immune disorders. Ab-proteases from MS, AIM and AIT patients exhibited specific proteolytic cleavage of MBP, CM and thyroid Ags (T3, T3, TPO), respectively The activity of the Ab-proteases markedly differs between: (i) the patients and healthy controls, and (ii) different clini-cal courses, to to predict transformation prior to changes of the clinical course. The activity of Ab-proteases was first registered at the subclinical stages 1-5 years (regardless to type of the dis-order) prior to the clinical illness. Some (12-24%) of the direct disease-related relatives are sero-positive for low-active Ab-proteases from which seropositive relatives established were being monitored for 2-3 years whilst demonstrating a stable growth of the Ab-associated proteolytic activity. We saw also low-active Ab-proteases in persons at MS-, AIM- and AIT-related risks (at the subclinical stages), and primary clinical, ultrasonic and MRT manifestations observed were coincided with the activity to have its mid-level reached. The activity of Ab-proteases would confirm a high subclinical and predictive value of the translational tools as applicable for person-alized monitoring protocols. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism. Of tremendous value are Ab-proteases directly affecting the physiologic remodeling of tissues with multilevel architecture. Further studies on targeted Ab-mediated proteolysis may provide a supplementary tool for predicting exacerbations and thus the disability of the MS, AIM and AIT patients.

Biography :

Sergey Suchkov completed his Graduation and MD from Astrakhan State Medical University. He completed his PhD at I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology and Doctor Degree at National Institute of Immunology, Russia. From 1989 to 1995, he was a Head of Lab of Clinical Immunology and Immuno-biotechnology at Helmholtz Eye Research Institute in Moscow. From 1995 to 2004, he was a Chair in Department for Clini-cal Immunology, Moscow Clinical Research Institute (MONIKI). From 1993-1996, he was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. Presently, he is a Professor in Department of Pathology, I.M. Sechenov First Moscow State Medical Uni-versity and Department of Clinical Immunology, A.I. Evdokimov Moscow State Medical and Dental University; Dean in Department of PPPM Development and the First Vice-President at University of World Politics and Law, Moscow, Russia and; Secretary General at United Cultur-al Convention (UCC), Cambridge, UK. He is an author of more than 500 publications including 10 patents and more than 10 monographs, handbooks and textbooks published in Russia and USA. He is a member of New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA and; European Association for Medical Education (AMEE), Dundee, UK.

Email: ssuchkov57@gmail.com